Intellia Therapeutics Inc (NASDAQ:NTLA)

60.57
Delayed Data
As of Jul 06
 -2.67 / -4.23%
Today’s Change
37.08
Today|||52-Week Range
180.59
-48.77%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$4.1B

Company Description

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Contact Information

Intellia Therapeutics, Inc.
40 Erie Street
Cambridge Massachusetts 02139
P:(857) 285-6200
Investor Relations:

Employees

Shareholders

Mutual fund holders54.81%
Other institutional27.86%
Individual stakeholders22.23%

Top Executives

John M. LeonardPresident, Chief Executive Officer & Director
Glenn GoddardTreasurer, Chief Financial & Accounting Officer
Laura Sepp-LorenzinoChief Scientific Officer & Executive VP
David LebwohlChief Medical Officer & Executive Vice President
Eliana ClarkChief Technology Officer & Executive VP